-
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Monday, May 22, 2017 - 12:25pm | 600Read More...Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...
-
Mylan Is 'Comfortable Moving Forward' With Acquisition Of Sweden-Based Meda
Wednesday, April 6, 2016 - 1:23pm | 177Read More...Mylan NV (NASDAQ: MYL) announced in early February it had entered into an agreement to acquire Sweden-based Meda. Following the breakup of Pfizer Inc. (NYSE: PFE)'s proposed merger with Allergan plc Ordinary Shares (NYSE: AGN), investors are focusing in on other active M&A deals within the...
-
Vetr Top Raters Pound Table On Mylan, 87% Bullish
Friday, February 12, 2016 - 1:03pm | 178Read More...Shares of Mylan NV (NASDAQ: MYL) tumbled nearly 20 percent on Thursday after the company announced a massive $7.2 billion acquisition of Meda, a Sweden-based drugmaker. The stock's plunge likely prompted Vetr top raters to upgrade Mylan's stock rating to a five star out of five-star rating. In fact...
-
Market Wrap For April 4: Dow Suffers Triple Digit Point Loss, Nasdaq Continues To Underperform
Friday, April 4, 2014 - 4:44pm | 2444Read More...U.S. stocks ended the week on a sour note as investors continue to sell many momentum names. Not helping the bull case was the much anticipated Jobs report number which failed to "wow" the market, coming in relatively in-line with expectations. The Dow suffered a triple digit point loss and...
